Sorafenib and Radioembolization With Sir-Spheres for the Treatment of Metastatic Ocular Melanoma
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions; Biomarker
- 31 Aug 2018 Biomarkers information updated
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.